Skip to main content

Table 2 Cox proportional hazards model assessing factors associated with overall survival (OS) and cause-specific survival (CSS) before propensity score matching

From: Marital status, an independent predictor for survival of gastric neuroendocrine neoplasm patients: a SEER database analysis

Variable

OS

CSS

Crude HR (95% CI)

P

Adjusted HR (95% CI)

P

Crude HR (95% CI)

P

Adjusted HR (95% CI)

P

Marital status

 Married

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

 Divorced/Separated

1.19 (1.00–1.43)

0.06

1.44 (1.20–1.74)

< 0.001

1.09 (0.83–1.43)

0.56

1.35 (1.02–1.80)

0.04

 Single

1.06 (0.91–1.24)

0.44

1.43 (1.22–1.68)

< 0.001

1.05 (0.83–1.31)

0.71

1.22 (0.96–1.56)

0.11

 Widowed

3.35 (2.05–2.68)

< 0.001

1.56 (1.35–1.81)

< 0.001

1.80 (1.46–2.22)

< 0.001

1.33 (1.05–1.68)

0.02

Age at diagnosis

 ≤ 50

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

 51–70

2.10 (1.76–2.50)

< 0.001

2.16 (1.80–2.58)

< 0.001

1.55 (1.22–1.96)

< 0.001

1.54 (1.20–1.96)

0.001

 > 70

5.75 (4.83–6.84)

< 0.001

5.28 (4.38–6.38)

< 0.001

3.27 (2.57–4.15)

< 0.001

2.76 (2.12–3.61)

< 0.001

Sex

 Male

1.56 (1.41–1.73)

< 0.001

1.48 (1.32–1.65)

< 0.001

2.15 (1.84–2.52)

< 0.001

1.30 (1.09–1.55)

0.003

 Female

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

Year of diagnosis

 1973–1995

1.70 (1.38–2.10)

< 0.001

1.93 (1.54–2.42)

< 0.001

1.69 (1.25–2.29)

0.001

1.87 (1.34–2.60)

< 0.001

 1996–2005

1.58 (1.35–1.86)

< 0.001

1.66 (1.40–1.98)

< 0.001

1.46 (1.17–1.81)

0.001

1.56 (1.22–2.00)

< 0.001

 2006–2010

1.14 (0.96–1.34)

0.15

1.15 (0.97–1.36)

0.12

1.16 (0.93–1.46)

0.19

1.17 (0.93–1.47)

0.19

 2011–2015

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

Ethnicity

 White

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

 Black

1.12 (0.97–1.30)

0.11

1.18 (1.02–1.37)

0.03

1.14 (0.91–1.42)

0.25

1.18 (0.89–1.40)

0.34

 Others

1.05 (0.85–1.30)

0.64

0.97 (0.78–1.20)

0.78

1.63 (1.24–2.14)

< 0.001

1.23 (0.93–1.63)

0.15

Grade

 Well differentiated

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

 Moderately differentiated

1.76 (1.33–2.34)

< 0.001

1.60 (1.20–2.12)

< 0.001

2.99 (1.95–4.57)

< 0.001

2.05 (1.33–3.15)

0.001

 Poorly differentiated

8.46 (6.98–10.25)

< 0.001

2.93 (2.38–3.62)

< 0.001

23.87 (17.80–32.02)

< 0.001

4.40 (3.21–6.02)

< 0.001

 Undifferentiated

8.11 (6.00–10.96)

< 0.001

3.51 (2.56–4.80)

< 0.001

22.06 (15.04–32.36)

< 0.001

4.71 (3.16–7.02)

< 0.001

 Unknown

1.51 (1.28–1.77)

< 0.001

1.11 (0.94–1.31)

0.23

1.84 (1.38–2.45)

< 0.001

1.30 (0.96–1.77)

0.09

Tumour stage

 Localized

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

 Regional

2.83 (2.35–3.41)

< 0.001

2.16 (1.77–2.64)

< 0.001

11.12 (8.54–14.47)

< 0.001

7.15 (5.37–9.52)

< 0.001

 Distant

7.54 (6.62–8.58)

< 0.001

4.36 (3.73–5.09)

< 0.001

32.34 (26.20–39.92)

< 0.001

15.83 (12.37–20.27)

< 0.001

 Unknown

1.37 (1.17–1.60)

< 0.001

0.93 (0.79–1.10)

0.42

1.97 (1.44–2.71)

< 0.001

1.35 (0.97–1.88)

0.08

Size (cm)

 ≤ 5

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

 5.1–10.0

0.90 (0.60–1.35)

0.62

0.97 (0.64–1.45)

0.87

1.53 (0.62–3.79)

0.36

1.62 (0.65–4.02)

0.30

 > 10.0

1.71 (1.22–2.39)

0.002

0.94 (0.67–1.33)

0.74

6.37 (2.96–13.70)

< 0.001

1.58 (0.73–3.45)

0.25

 Unknown

1.10 (0.81–1.49)

0.55

0.96 (0.70–1.32)

0.81

2.26 (1.07–4.78)

0.03

1.17 (0.55–2.50)

0.69

Surgery

 Performed

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

 Not Performed

2.22 (1.99–2.46)

< 0.001

1.67 (1.47–1.89)

< 0.001

3.13 (2.65–3.69)

< 0.001

1.95 (1.59–2.39)

< 0.001

 Unknown

1.71 (1.15–2.56)

0.008

2.03 (1.36–3.02)

0.001

2.22 (1.27–3.88)

0.005

2.42 (1.36–4.29)

0.003

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us